ezetimibe has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ford, GA; Hamed, J; Kearney, M; Metcalfe, AM; Newton, JL; Williams, H | 1 |
| Cheng, K; Cicurel, A; Feldhamer, I; Israel, A; Lavie, G; Ruppin, E; Schäffer, AA; Schiff, E; Sinha, S; Tal, A | 1 |
2 other study(ies) available for ezetimibe and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Optimizing lipid management-impact of the COVID 19 pandemic upon cardiovascular risk in England.
Topics: Cardiovascular Diseases; Cholesterol; Communicable Disease Control; COVID-19; Ezetimibe; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pandemics; Risk Factors; State Medicine | 2023 |
Identification of drugs associated with reduced severity of COVID-19 - a case-control study in a large population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Case-Control Studies; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Ezetimibe; Female; Hospitalization; Humans; Male; Middle Aged; Odds Ratio; Rosuvastatin Calcium; SARS-CoV-2; Severity of Illness Index; Ubiquinone; Vitamin D; Young Adult | 2021 |